SAN DIEGO, March 19, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the “101 Transaction”) by Inhibrx, Inc. (the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
